|
Real-time Estimate
Cboe BZX
01:08:26 13/02/2026 am IST
|
5-day change
|
1st Jan Change
|
|
123.24 USD
|
-10.34%
|
 |
-10.86%
|
-13.31%
|
| 10:07pm |
Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says
|
MT
| |
12/02 |
Neurocrine Biosciences Fiscal Q4 Adjusted Earnings, Revenue Rise; Sets INGREZZA FY Guidance
|
MT
| |
12/02 |
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M
|
MT
| |
12/02 |
Neurocrine Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
|
CI
| |
12/02 |
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M
|
MT
| |
12/02 |
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q4 Adjusted EPS $1.88 per Share, vs. FactSet Est of $1.80
|
MT
| |
12/02 |
Neurocrine Biosciences, Inc. Provides Product Sales Guidance for the Fiscal Year 2026
|
CI
| |
26/01 |
Neurocrine Biosciences, Inc. Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
|
CI
| |
22/01 |
Immedica Pharma AB completed the acquisition of Diurnal Group Limited from Neurocrine Biosciences, Inc..
|
CI
| |
15/01 |
Neurocrine Biosciences, Inc. Presents Head-To-Head INGREZZA (Valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
|
CI
| |
15/01 |
Neurocrine Biosciences, Inc. Presents Head-To-Head INGREZZA (Valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
|
CI
| |
08/01 |
Immedica Pharma AB entered into a definitive agreement to acquire Diurnal Group Limited from Neurocrine Biosciences, Inc. for $65 million.
|
CI
| |
30/12 |
XOMA Royalty Corporation Amends Its Collaboration with Takeda Through Strategic Royalty Share Transaction
|
CI
| |
23/12 |
Neurocrine's movement disorder treatment fails late-stage trial
|
RE
| |
23/12 |
Neurocrine Biosciences, Inc. Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
|
CI
| |
20/11 |
Neurocrine Biosciences, Inc. Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors
|
CI
| |
11/11 |
Neurocrine Biosciences, Inc. Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
|
CI
| |
03/11 |
TransThera Sciences Sells NLRP3 Inhibitor License to Neurocrine Bioscience
|
MT
| |
03/11 |
TransThera Sciences, Inc. Announces Collaboration with Neurocrine
|
CI
| |
29/25/29 |
Neurocrine Biosciences Q3 Adjusted Earnings, Revenue Rise
|
MT
| |
29/25/29 |
Neurocrine Biosciences reports 28% jump in Q3 net sales, EPS beats estimates
|
RE
| |
29/25/29 |
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q3 Revenue $794.9M, vs. FactSet Est of $746.8M
|
MT
| |
29/25/29 |
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q3 Adjusted EPS $2.17 per Share, vs. FactSet Est of $2.07
|
MT
| |
29/25/29 |
Tranche Update on Neurocrine Biosciences, Inc.'s Equity Buyback Plan announced on February 21, 2025.
|
CI
| |
29/25/29 |
Neurocrine Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
|
CI
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
